My thoughts is that the update will be focused on HRV and lani. Market volatility may be used to delay listing. I would still list on NASDAQ but I could see te logic of a delay. Key point I'll be making is that you want to list before a phase 2b success. News drives volume and price in us biotech land.
Add to My Watchlist
What is My Watchlist?